Brain metastases at the time of presentation of non-small cell lung cancer: a multi-centric AERIO analysis of prognostic factors by Jacot, W et al.
Patients with lung cancer frequently suffer from brain metastases
at the time of presentation. This condition affects approximately
10% of non-small cell lung cancer (NSCLC) patients (Newman
and Hansen, 1974; Sorensen et al, 1988). Surgery is feasible only
for a small proportion of these patients. Whole brain radiotherapy
has been, hitherto, the generally recommended treatment in inop-
erable patients. The survival of NSCLC patients with brain meta-
stases is poor, reported to be between 3 to 6 months in patients
treated with medical therapies, either radiotherapy or chemotherapy
(compared to 6–10 months in other advanced NSCLC (Paesmans et
al, 1995; Shepherd, 1999)). Furthermore, brain metastases at the
time of presentation of lung cancer seems to be a worse prognosis
(Sorensen et al, 1988) than metachronous brain metastases. 
New therapeutic strategies are needed to improve the outcome
of these patients. The knowledge of prognostic determinants might
be important in both clinical trials and routine practice (Komaki
et al, 1993; Charloux et al, 1997; Paesmans et al, 1997; Merrill 
et al, 1999). In the former setting, prognostic co-variables must be
taken into account in survival analyses; by way of illustration, in a
given randomized trial, the statement that a difference in survival
is related to the effects of the treatment must be supported by a
proportional hazards model demonstrating that this effect does not
depend on well-known prognostic determinants (Depierre et al,
1999; Furuse et al, 1999). In the second setting, a therapeutic deci-
sion might be influenced by the state of prognostic variables
(Komaki et al, 1993). 
Here we especially take a look at the prognostic significance of
2 specific serum markers, CYFRA 21-1 and neuron-specific
enolase (NSE). The prognostic value of CYFRA 21-1 (a fragment
of cytokeratin subunit 19) in this disease has been suggested (Pujol
et al, 1993; Wieskopf et al, 1995; Brechot et al, 1997). NSE, the g-
subunit of enolase, has been widely investigated as a marker of
small cell lung cancer (SCLC; Jorgensen et al, 1989). Although
only a small proportion of NSCLC presented with a high NSE
level, this marker might indirectly reflect; i) a neuroendocrine
component of the disease in favour of tumour heterogeneity; ii) a
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Summary A multi-centre retrospective study involving 4 French university institutions has been conducted in order to identify routine pre-
therapeutic prognostic factors of survival in patients with previously untreated non-small cell lung cancer and brain metastases at the time of
presentation. A total of 231 patients were recorded regarding their clinical, radiological and biological characteristics at presentation. The
accrual period was January 1991 to December 1998. Prognosis was analysed using both univariate and multivariate (Cox model) statistics.
The median survival of the whole population was 28 weeks. Univariate analysis (log-rank), showed that patients affected by one of the
following characteristics proved to have a shorter survival in comparison with the opposite status of each variable: male gender, age over 63
years, poor performance status, neurological symptoms, serum neuron-specific enolase (NSE) level higher than 12.5 ng ml–1, high serum
alkaline phosphatase level, high serum LDH level and serum sodium level below 132 mmol l–1. In the Cox’s model, the following variables
were independent determinants of a poor outcome: male gender: hazard ratio (95% confidence interval): 2.29 (1.26–4.16), poor performance
status: 1.73 (1.15–2.62), age: 1.02 (1.003–1.043), a high serum NSE level: 1.72 (1.11–2.68), neurological symptoms: 1.63 (1.05–2.54), and
a low serum sodium level: 2.99 (1.17–7.62). Apart from 4 prognostic factors shared in common with other stage IV NSCLC patients, whatever
the metastatic site (namely sex, age, gender, performance status and serum sodium level) this study discloses 2 determinants specifically
resulting from brain metastasis: i.e. the presence of neurological symptoms and a high serum NSE level. The latter factor could be in
relationship with the extent of normal brain tissue damage caused by the tumour as has been demonstrated after strokes. Additionally, the
observation of a high NSE level as a prognostic determinant in NSCLC might reflect tumour heterogeneity and understimated neuroendocrine
differentiation. © 2001 Cancer Research Campaign http://www.bjcancer.com
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in NSCLC patients with brain metastases at the time of presenta-
tion, we conducted a retrospective study. 
PATIENTS AND METHODS 
Patient selection 
This is a multi-centre retrospective study involving 4 French univer-
sity institutions (Montpellier university hospital, Institut Gustave
Roussy, Strasbourg university hospital and Besançon university
hospital). In the past, these institutions were involved in numerous
cancer trials and therefore they possess comprehensive patient data-
bases. Case reports extracted from these databases were selected on
the following criteria: histologically proven NSCLC, brain meta-
stasis at the time of presentation as demonstrated either by
computed tomography (CT) or magnetic resonance imaging (MRI),
no prior anti-cancer therapy. The accrual period was January 1991 to
December 1998. Histological sub-classification was done according
to the WHO classification (World Health Organization, 1982).
Staging was carried out by exhaustive procedures according to the
4th edition of the Union Internationale Contre le Cancer (UICC)
tumour node metastases (TNM) classification (Sobin et al, 1987)
and the American Thoracic Society map of regional pulmonary
nodes (Tisi et al, 1982). By definition, all patients belonged to stage
IV of the new Mountain’s stage grouping (Mountain, 1997) 
Data collection 
For each patient, the following pre-treatment characteristics were
recorded: age, sex, performance status (estimated according to the
Eastern Cooperative Oncology Group (Zubrod et al, 1960)),
percentage of weight loss during the previous 4 months, tumour
and nodal status, histology, clinical symptoms belonging to brain
metastases (i.e. intra-cranial hypertension, seizure, focal neurolo-
gical symptoms), other metastatic sites involved (i.e. liver, adrenal
glands, bone metastases), serum CYFRA 21-1 level (upper limit of
normal values: 3.6 ng ml–1), serum NSE level (upper limit of
normal values: 12.5 ng ml–1), serum alkaline phosphatase and
lactate dehydrogenase (LDH) levels (either normal or elevated,
depending on the institution’s upper normal values), serum sodium
level (lower normal limit 132 mmol l–1), white blood cell count,
serum albumin level, number and location of brain metastases on
CT or MRI and finally, treatment modalities. 
Statistics 
Survival data were updated on February 1 1999. Survival was
defined as the time from histological diagnosis to the date of death.
Death related to the disease whichever the progression site, or
related to its treatment was analysed as an event. Deaths from
other causes were treated as censored observations (myocardial
infarctions or pulmonary embolisms). Survival was estimated by
the Kaplan–Meier method (Kaplan and Meier, 1958). Single vari-
able survival analyses were done by means of log-rank tests. 
Coding methods for the different variables depended on their
nature. Some of the variables have been extensively described in
the literature therefore the threshold has been defined from
previous publications. Performance status has been analysed
according to 2 classical modalities: PS 0–1 and PS greater or equal
to 2 (Zubrod et al, 1960). The effect of nodal status on prognosis
was tested according to the presence or the absence of mediastinal
lymph node involvement. The same coding regarding tumour status
has been adopted according to the new Mountain’s stage grouping
(Mountain, 1997). Regarding biological variables, including
tumour markers we used previously published thresholds: 3.6 ng
ml–1 for CYFRA 21-1 (Pujol et al, 1993). The threshold values for
serum NSE levels to be used in clinical studies have been defined
from publications describing this neuroendocrine marker (Cooper
and Splinter, 1987; Jorgensen et al, 1989). The treatment modality
was not tested as a prognostic variable inasmuch as treatment was
decided according to each institution’s procedure and was based
upon the different pre-treatment variables. 
Multivariate regression was done with the Cox model (Cox,
1972; Andersen, 1991). The forward selection of variable proced-
ure has been used. The selection of variables to be tested in the
Cox model was made using the results of univariate analysis i.e.
variables reaching at least a P level less than 15%. This model was
written after a binary coding of the significant variables (except
for age which was analysed as a continuous variable): categorical
variables (such as performance status) were transformed into
binary variables (0: negative or 1: positive). The number of levels
of a categorical variable needed to describe a predictive factor is
one less than the categories of that factor inasmuch as its baseline
level is defined by setting the value of each of the categorical vari-
ables at zero. The significance of the effect of a given factor was
assessed by determining whether or not the coefficient assigned to
one or more of its categories was sufficiently different from zero.
The proportional hazard assumption for each of the selected vari-
ables retained in the final model was originally checked by plot-
ting the log cumulative baseline hazard ratio. A P level of less than
0.05 was considered significant. SAS software package was used. 
According to the above-mentioned procedure, 14 variables were
selected as putative prognostic determinants to be tested in the
Cox regression hazard model. They represented less than 10% of
the total of observed events (207 deaths) and therefore complied
with the current recommendation (Harrell et al, 1985). 
RESULTS 
Patient’s characteristics are summarized in Table 1. Most of the
main characteristics of NSCLC were retrieved particularly a
median age of 59 years (range, 32–85 years). 85 patients (37%)
did not have symptoms related to the brain metastases and
the disease was disclosed by a pre-treatment staging procedure
including CT scan. 134 patients suffered from neurological
symptoms, consisting of intra-cranial hypertension symptoms (33
patients), seizure, epilepsy or muscle weakness (101 patients) or
an association of these different symptoms. There were 6 deaths
related neither to the disease nor to the treatment. These observa-
tions have been censored. At the time of analysis, 207 deaths had
been reported and 24 (10%) patients were still alive. In the whole
patient population, median survival was 28 weeks (95% confid-
ence interval [CI], 24 to 34 weeks). The 1- and 2-year survival
rates were 25% (95% CI, 19–31%) and 8% (95% CI, 4–11%),
respectively (Figure 1). 
Univariate analysis 
Univariate analysis (Table 2) showed that patients affected by one
of the following characteristics proved to have a shorter survival in
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age over 63 years, performance status equal to or worse than 2,
neurological symptoms (Figure 2), serum NSE level higher than
12.5 ng ml–1 (Figure 3), high serum alkaline phosphatase level, 
high serum LDH level and serum sodium level lower than
132 mmol l–1. 
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Table 1 Patients’ characteristics 
Variables  No. of patients (%) 
Total  231 
Age (years) Median ± SD 59 ± 11 
< 40 13 (6) 
40–49 49 (21) 
50–59 65 (28) 
60–69 70 (30) 
70 and over 34 (15) 
Male gender Male 194 (84) 
ECOG performance status 0 44 (19) 
1 92 (40) 
2 60 (26) 
3 26 (11) 
4 9 (4) 
Tumour status 1–2 107 (47) 
3–4 122 (53) 
Nodal status 0–1 64 (28) 
2–3 165 (71) 
Histology Squamous cell carcinoma 95 (41)  
Adenocarcinoma 86 (37) 
Large cell carcinoma 50 (22) 
Weight loss (%) < 5% /³ 5% 119 (52)/88 (38) 
Unknown 24 (10) 
Serum Cyfra 21–1 level < 3.6 /³ 3.6  58 (25)/88 (38) 
Unknown 85 (37) 
Serum NSE level ≤ 12.5 /> 12.5 142 (61)/57 (25) 
Unknown 32 (14) 
Serum albumin level <32 g l–1 /³ 32 g l–1 159 (69)/27 (12) 
Unknown 45 (19) 
Serum sodium level <132 mmol l–1 /³ 132 mmol l–1 219 (95)/10 (4) 
Unknown 2 (1) 
Alkaline phosphatase Normal/elevated 180 (78)/41 (18) 
Unknown 10 (4) 
Lactate dehydrogenase level Normal/elevated 133 (58)/78 (34) 
Unknown 20 (9) 
Blood leucocyte count ≤ 10 000 ml–1> 10 000 ml 108 (47)/120 (52) 
Unknown 3 (1) 
Adrenal gland metastases Yes/No 34 (15)/197 (85) 
Bone metastases Yes/No 47 (20)/184 (80) 
Liver metastases Yes/No 24 (10)/207 (90) 
No. of brain metastases Unique/Multiples 89 (39)/125 (54) 
Unknown 17 (7) 
Site of brain metastases Supra/Infra-tentorial 144 (62) / 19 (8) 
Mixed 49 (21) 
Unknown 19 (8) 
Neurologic symptoms No/Yes 85 (37)/134 (58) 
Treatment modalities Best Supportive Care 19 (8%) 
Radiotherapy 13 (6%) 
Chemotherapy 41 (18%) 
Surgery 0 
Surgery + Chemotherapy 2 (1%) 
Surgery + Radiotherapy 2 (1%) 
Surgery + Chemo. + Radio. 3 (1%) 
Radiotherapy + Chemotherapy 150 (65%) 
Brain response to treatment Yes/No 93 (40)/107 (46) 
Unknown 31 (13) Multivariate analysis 
According to the above-mentioned procedure, 14 variables were
selected as putative prognostic determinants to be tested in the Cox
regression hazard model (sex, age, performance status, histology,
serum NSE level, serum CYFRA 21-1 level, serum albumin, alka-
line phosphatases, LDH, serum sodium, blood leucocyte count,
presence of bone metastases, presence of liver metastases, neurolo-
gical symptoms). They represented less than 10% of the total
observed events (207 deaths) and therefore complied with the
current recommendation (Harrell et al, 1985). 
The following variables were independent determinants of a poor
outcome: male gender: hazard ratio (95% confidence interval): 2.29
(1.26–4.16), poor performance status: 1.73 (1.15–2.62), age: 1.02
(1.003–1.043), a high serum NSE level: 1.72 (1.11–2.68), neurolo-
gical symptoms: 1.63 (1.05–2.54), and a low serum sodium level:
2.99 (1.17–7.62) (Table 3). 
Finally, patients have been coded according to the presence or
absence of a major metastatic site (i.e. presence of at least one
of the following metastatic sites: liver or adrenal or bone). This
variable did not modify the results of the Cox model. 
DISCUSSION 
Brain metastases at the time of presentation of NSCLC are a
frequent clinical problem. Classically, treatment consists of whole
brain radiotherapy. Surgery is usually proposed to the small subset
of patients presenting with a single brain metastasis and for whom
primary site can be controlled. The role of chemotherapy in the
management of NSCLC with brain involvement remains controver-
sial. Short life expectancy is generally considered as a deterrent to
curative intent. However, recent studies indicate that chemotherapy
is active on brain metastases of NSCLC (Ellis et al, 1998; Kelly and
Bunn, 1998; Postmus and Smit, 1999). In addition, new therapies
such as radiosurgery and combined chemotherapy-radiotherapy are
being developed for these patients. Therefore, the appraisal of the
prognostic factor is mandatory. 
We report herein a survival analysis of a homogeneous popu-
lation of NSCLC patients with brain metastases at the time of
presentation. 4 prognostic factors elicited from this study are clas-
sical survival determinants reported to be shared in common by all
NSCLC whatever the metastatic site (Zimm et al, 1981; Diener-
West et al, 1989; Komarnicky et al, 1991; Lonjon et al, 1994; 
Ryan et al, 1995; Ando et al, 1996; Auchter et al, 1996; Gaspar 
et al, 1997; Hsiung et al, 1998; Agboola et al, 1998; Lagerwaard et al,
1999), or by brain metastases whatever the primary tumour (Zimm
et al, 1981; Diener-West et al, 1989; Komarnicky et al, 1991;
Lonjon et al, 1994; Auchter et al, 1996; Gaspar et al, 1997;
Agboola et al, 1998; Lagerwaard et al, 1999). These factors are
gender, performance status, age and serum sodium level. 
Apart from the above-mentioned factors, our study disclosed
2 determinants which might result from brain metastases: the
presence of neurological symptoms and a high serum NSE level.
Clinical symptoms related to the brain metastases were the only
site-specific factor independently affecting survival. Neither the
number nor the location of brain metastases were statistically
significant determinants of prognosis. This finding contrasts with
some other studies also aimed at prognosticating the outcome of
patients suffering from brain metastases (Zimm et al, 1981; Swift
et al, 1993; Nussbaum et al, 1996; Sen et al, 1998). However, one
can mention that these determinants vary from one study to
another (Zimm et al, 1981; Swift et al, 1993; Ando et al, 1996;
Nussbaum et al, 1996; Hsiung et al, 1998; Nguyen et al, 1998; Sen
et al, 1998). This discrepancy could be in relationship with a
possible underestimation of the number of metastases and the
tumour burden shown by means of CT scan. Therefore, the case of
anatomic characteristics of brain metastases seems of less pro-
gnostic importance than the presence of symptoms by themselves.
This statement does not minimize the paramount consequence of
anatomic characterization of brain disease in treatment decision. 
The gg isomer of the ubiquitous enzyme enolase referred to as
NSE is the most widely used neuroendocrine serum marker in
SCLC clinical management (Cooper and Splinter, 1987; Jorgensen
et al, 1989). In the NSCLC histology, the evaluation of this
neuroendocrine marker might seem unexpected. However, the
common endodermal origin of all histological types of lung cancer
makes it possible to include SCLC and NSCLC in a unique spec-
trum of differentiation with frequent overlaps (Yesner and Carter,
1982). Early studies using histology (Yesner and Carter, 1982) or
electronic microscopy (Gould et al, 1983) have demonstrated that
mixed SCLC-NSCLC may be observed in a low proportion of all
lung cancers. Patients with mixed SCLC-large cell carcinoma
proved to have a shorter survival than those with pure histological
906 W Jacot et al
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Figure 1 Kaplan–Meier estimation of overall survival in the whole
population of non-small cell lung cancer patients suffering from brain
metastases at the time of presentation
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Figure 2 Probability of survival of non-small cell lung cancer patients with
or without neurological symptomsSCLC suggesting that this heterogeneity has clinical relevance
(Radice et al, 1982). Therefore, we decided to evaluate this marker
in the particular setting of brain metastasis of NSCLC. 
In our study patients with a pre-treatment high serum NSE level
proved to have a poor outcome. Two hypotheses could explain this
finding and they are not mutually exclusive. First, this high NSE
level might reflect a neuroendocrine differentiation. This hetero-
topic antigen expression could be regarded as a consequence of a
phenotypic heterogeneity, a unique characteristic of human malig-
nancy thought to be in relationship with genotypic instability and
tumour progression (Nicolson, 1987). Alternatively, high serum
NSE levels may reflect the extent of the neuronal damage. One
piece of evidence which can support this hypothesis is the relation-
ship between the degree of neuronal damage and the serum NSE
level following a cerebral stroke (Cunningham et al, 1991, 1996;
DeGiorgio et al, 1995, 1999; Fogel et al, 1997; Missler et al, 1997;
Martens et al, 1998; Buttner et al, 1999; Schoerkhuber et al, 1999;
Wunderlich et al, 1999) or other neuronal brain damage
(DeGiorgio et al, 1995, 1999; Fogel et al, 1997; Martens et al,
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Table 2 Univariate analysis 
Variable Median survival (weeks) P (Log- rank) 
Age (year) ≤ 63 33.7 0.0363 
> 63 21.4
Gender Female 50.7 0.0004 
Male 26.3
ECOG performance status < 2 35.3 0.0003 
³ 2 20.9
Tumour status (T) 1–2 30.6 0.2923 
3–4 26.9
Nodal status (N) 0–1 27.3 0.2247 
2–3 29.6
Histology Squamous-cell carcinoma 26.3 0.1075 
Adenocarcinoma 32.7
Large cell carcinoma 28.4
Weight loss < 5% 28.4 0.4312 
³ 5% 27.3
Serum Cyfra 21–1 level ≤ 3.6 33.6 0.1314 
> 3.6 24.6
Serum NSE level ≤ 12.5 34.4 0.0015 
> 12.5 24.3
Serum albumin level < 32 g l–1 20.1 0.1293 
³ 32 g l–1 31.4 
Serum sodium level < 132 15.4 0.0141 
³ 132 30.1 
Serum alkaline phosphatase level Normal 32.3  0.0080 
Elevated 20.6 
Serum lactate Normal 33.6 0.0358 
dehydrogenase level Elevated 23.6
Blood leukocyte count ≤ 10.109 l–1 33.6 0.1005 
> 10.109 l–1 27 
Adrenal gland metastases Yes 24.3 0.4637 
No 29.6 
Bone metastases Yes 23.9 0.0663 
No 30.3 
Liver metastases Yes 24.1 0.1414 
No 28.4 
No. of brain metastases Unique 30.6 0.1675 
Multiples 28 
Site of brain metastases Supra-tentorial 32.3  0.7317 
Infra-tentorial 27.3 
Mixed 26.9 
Neurologic symptoms No symptoms 38.7 0.0019 
Neurologic symptoms 24.3
Table 3 Estimated hazard ratio for significant variables 
Variables Hazard ratio 95% CI P
Male gender 2.29 1.26–4.16 0.006 
Poor performance status (2–4) 1.73 1.15–2.62 0.009 
Age 1.02 1.003–1.043 0.021 
High serum NSE level 1.72 1.11–2.68 0.016 
Presence of neurological 
symptoms 1.63 1.05–2.54 0.026 
Low serum sodium level 2.99 1.17–7.62  0.022 1998; Buttner et al, 1999; Schoerkhuber et al, 1999). In these
diseases, the serum NSE level exhibits a prognostic indication
inasmuch as studies have found a close relationship between the
volume of affected neuronal tissue and the serum NSE level
(Cunningham et al, 1991, 1996; Missler et al, 1997; Wunderlich et al,
1999). We hypothesize that the poor outcome of patients with a
high NSE level and brain metastasis is due to the severity of
normal neuronal tissue damage surrounding metastases. However,
the latter explanation and the first hypothesis, i.e. serum NSE as a
marker of phenotypic heterogeneity, are not mutually exclusive. 
One may hypothesize that, due to the retrospective nature of the
herein study, a possible bias was introduced by the treatment
heterogeneity (as shown in Table 1). Patients received a combin-
ation of chemotherapy or chemo-radiotherapy according to each
centre’s policy. Each indication was based upon specific variables
such as solitary or multiple brain metastases, performance status,
etc. This treatment heterogeneity mainly reflects the lack of
consensus regarding the management of NSCLC patients affected
by brain metastases at time of presentation. There is no clear
demonstration in the literature that a given drug combination or a
given combined modality could be considered as a standard
regimen. In addition, in our population, the distribution of serum
NSE levels did not differ according to treatment modality
suggesting that the prognostic significance of the marker was not
affected by therapy. 
The present manuscript reports an exploratory multi-centre
study with identification of prognostic determinants taken as the
primary endpoint. Therefore, it would be hazardous to draw
specific treatment recommendations from our data. According to
the classification proposed by Simon and Altman (1994), the study
herein could be considered as a type 2 prognostic factor investiga-
tion. The findings of the current study deserve further confirm-
atory investigations in a larger population of patients with
homogeneous therapeutic strategies. Such phase III studies are
considered as the only means ‘to determine which subsets of
patients benefit from a given therapy’. 
In conclusion, our study confirms age, sex and performance
status as prognostic factors of NSCLC with brain metastases at the
time of presentation suggesting that this subset of patients shares
similar determinants of outcome with the general NSCLC popula-
tion. In addition, both neurological symptoms and serum NSE
levels are site-specific predictors of outcome to be taken into
account in new therapeutic approaches in this setting. 
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